Lupin commences business
Lupin Laboratories Pvt. Ltd. is incorporated
First Formulation Plant and R&D Center at Aurangabad is commissioned
Production of Ethambutol API starts
The Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar go on stream
Lupin Human Welfare and Research Foundation (LHWRF) is founded by Desh Bandhu Gupta
Joint Venture in Thailand is established
USFDA approvals for Ankleshwar and Mandideep plants received
Initiates production of Injectable Cephalosporins (API and Finished Product) at Mandideep
Fermentation Plant at Lupin Chemicals Ltd. Tarapur, Maharashtra established
Commissions Sterile Plant for Injectable Cephalosporins (API) at Mandideep
IPO of Lupin Laboratories Ltd. and Lupin Chemicals Ltd.
USFDA approval for Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur
UK MCA approval for the Injectable Cephalosporin Finished Product Plant at Mandideep
UK MCA approval for the Injectable Cephalosporin API plant at Mandideep
USFDA approval for Injectable Cefotaxime (API and Finished Product) at Mandideep
State-Of-The-Art R&D center, Lupin Research Park at Pune commissioned
Supply of Cephalosporin Finished Product to Alliance Partners in the US commences
Lupin Laboratories Ltd. is amalgamated with Lupin Chemicals Ltd., and retitled Lupin Ltd.
Exports to Advanced Markets cross INR 1000 Million
Patent filings cross 100
First 5 ANDAs filed
New Anti-TB Facility commissioned at Aurangabad
Rablet® rated by ORG-Marg as the second best launch in India in FY 2002-03
WHO approval for finished product facility at Aurangabad
SAP ERP implemented across the company to unify all business functions and processes
USFDA approval for the Oral Cephalosporin Plant at Mandideep
Lupin Pharmaceuticals Inc. USA, formed for commercialization activities in the US
Commences US Branded Business with the launch of Suprax®
Generics Business launched in the US with first 4 Products
USFDA approval for New Lovastatin Plant at Tarapur
USFDA approval for Goa finished product facility
Maiden Employees Stock Option Plan launched
UK MHRA and WHO approval for Goa finished product facility
Maiden bonus shares issued in the ratio of 1:1
Maiden Issue of Foreign Currency Convertible Bonds aggregating USD 100 Million
Acquired Kyowa Pharmaceutical Industry Company Ltd., a leading Generics Company in Japan
Vadodara based Rubamin Laboratories Ltd. acquired
Starts commercial production at the new finished product facility at Jammu
Biotech Facility in Pune set up
Acquired Hormosan Pharma Gmbh in Germany
Majority stake in Generic Health Pty Ltd., Australia acquired
Acquired majority stake in Pharma Dynamics, South Africa
Acquired the US Rights for Antara®
Majority stake in Multicare
Pharmaceuticals Philippines Inc. acquired
India Region Formulations (IRF) business crosses INR 1,000 Cr.
Commercial Production at the New Oral
Solid Dosage Facility at Pithampur commences
Acquires I’Rom Pharmaceuticals in Japan
India Formulations business inks its first in-license deal with Huminsulin®
Enters the Nifty 50 Index
Tonact® became the first Lupin brand to cross INR 100 Cr.
Joint Venture Agreement with Yoshindo Inc. in Japan to launch biosimilars
Acquires Laboratorios Grin, Mexico, Specialty Ophthalmic Company and with this enters the Latin American Market
Acquires Nanomi B.V. to enter the Complex Injectables Space
Center of Excellence for Inhalation Research in Coral Springs Florida inaugurated
Acquires Specialty Product Portfolio of Temmler Pharma GmbH & Co. in Germany
Acquires Medquimica Industria Farmaceutica S.A. in Brazil
Completes the acquisition of Pharma Dynamics in South Africa
India Formulations business crosses INR 3,000 Cr.
Bolsters the US Brands Portfolio with Methergine® Oral Tablets
Acquires Branded Product Portfolio from Shionogi & Co. Ltd. in Japan
Completes acquisition of US based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS)
Commissions new plant at Tottori, Japan
Forays into the OTC Segment with pan-India launch of Softovac®
Inaugurates a new plant at Sikkim
The number of sales representatives in India Formulations business crosses the 5,000 mark
Acquires Symbiomix Therapeutics, LLC in New Jersey for launch of Solosec®
Commissions Injectables Facility at Nagpur
Files New Drug Application for Etanercept Biosimilar in Japan
Signs deal with AbbVie for exclusive rights to develop and commercialize Lupin’s MALT1 inhibitors (oncology)
Inks partnership with Boehringer Ingelheim to develop and commercialize Lupin’s MEK inhibitors (oncology)
Orphan Drug NaMuscla® for treatment of non-dystrophic Myotonia launched in Europe
Receives European Marketing Authorization for Nepexto, Biosimilar Etanercept
Receives International Sustainability Rating System (ISRS) Certification for 4 sites
India Formulations business crosses INR 5,000 Cr.